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Abstract
Background: To design effective, tailored interventions to support antiretroviral therapy (ART) adherence, a
thorough understanding of the barriers and facilitators of ART adherence is required. Factors at the individual and
interpersonal level, ART treatment characteristics and health care factors have been proposed as important
adherence determinants.
Methods: To identify the most relevant determinants of adherence in northern Tanzania, in-depth interviews were
carried out with 61 treatment-experienced patients from four different clinics. The interviews were ad-verbatim
transcribed and recurrent themes were coded.
Results: Coding results showed that the majority of patients had basic understanding of adherence, but also
revealed misconceptions about taking medication after alcohol use. Adherence motivating beliefs were the
perception of improved health and the desire to live like others, as well as the desire to be a good parent. A de-
motivating belief was that stopping ART after being prayed for was an act of faith. Facilitators of adherence were
support from friends and family, and assistance of home based care (HBC) providers. Important barriers to ART
adherence were the use of alcohol, unavailability of food, stigma and disclosure concerns, and the clinics
dispensing too few pills. Strategies recommended by the patients to improve adherence included better Care and
Treatment Centre (CTC) services, recruitment of patients to become Home Based Care ( HBC) providers, and
addressing the problem of stigma through education.
Conclusion: This study underscores the importance of designing tailored, patient-centered adherence interventions
to address challenges at the patient, family, community and health care level.
Background
The availability and use of antiretroviral therapy (ART)
has increased considerably in Sub-Saharan Africa in re-
cent years. In Tanzania, 1.4 million people (5.7% of the
population aged 15–49 years) were living with HIV/
AIDS at the end of 2009. In the same year, 55.2% of the
425,725 Tanzanian children and adults in need of ART
were receiving it [1,2]. The clinical targets of ART have
been defined as full repression of viral multiplication,
restoration of the immune response, arresting the pro-
gression of disease, increasing survival rates, reducing
morbidity and enhancing the quality of life [3]. Acquisi-
tion of the full benefits of ART depend on continuously
high adherence to the medication (i.e., >90-95% correct
intake of prescribed doses) [4]. However, many patients
taking ART do not manage to achieve such high levels
of adherence [5].
To design effective adherence promoting interventions
that are sensitive to the local context, culture and facil-
ities, there is a need for a thorough understanding of the
relevant, modifiable behavioral determinants. Established
theories on health behavior suggest that the first possible
determinant is patients’ knowledge on adherence to
ART, based upon which people form their treatment
outcome expectancies [6]. Moreover, it is expedient to
examine motivational factors to adherence, which
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according to the Theory of Planned Behavior (TPB) [7]
comprise an attitudinal dimension (rational and
affective), a social dimension (i.e., the belief that one is
being supported or hindered in executing the behavior
by important others), as well as the patient’s confidence
in his or her ability to adhere to the required standards.
These 3 sources of motivation determine people’s behav-
ioral intentions (e.g., ‘I want to take these pills every
day’). However, the degree to which patients are success-
ful in translating their adherence intentions into behav-
ior may depend on experienced obstacles, facilitators,
and patients’ self-regulation skills to overcome these pro-
blems [8-10].The individual-level adherence determi-
nants can be influenced by the patient’s interpersonal
environment (e.g., practical support, stigma), the medi-
cation (e.g., side effects, complexity), and the health care
provided (e.g., the quality of adherence support at the
clinic, privacy at the clinic) [11-13]. Hence, adherence
determinant studies should try to understand patients’
emotions, cognitions and behaviors within their specific
context.
Although multiple studies on determinants of ART ad-
herence have been conducted in SSA, the continent is
large and consists of many different countries with their
own history, culture, health care system, infrastructure,
and so forth; factors that may present a unique mix of
challenges and resources for patients treated for HIV,
which are also likely to change over time. Despite studies
on determinants of ART adherence conducted in Tanza-
nia, still there is a need for through and updated under-
standing of adherence barriers and facilitators in order
to provide high-quality adherence support to secure
long-term treatment effectiveness and prevent resistance
development among HIV patients in Tanzania. This
study aimed to provide that understanding by combining
the virtues of qualitative research (e.g., detailed informa-
tion on particular beliefs and barriers, taking context
into account) with representativeness of the findings by
including a substantial number of patients from 4 differ-
ent HIV clinics.
Methods
Study site and participants
This qualitative study was conducted with patients in
Care and Treatment Centre (CTC) clinics located in three
rural and one urban hospital of the Tanzania Kilimanjaro
Region. Two of the four CTC clinics operate in hospitals
owned by religious institutions (Roman Catholic Church
and Evangelical Lutheran Church of Tanzania) while the
other two clinics are government-owned. All clinics offer
care to the general public, regardless of religious back-
ground (note that the great majority, more than 95%, of
the people are Christian). The number of patients using
ART in the included clinics range from 500–1500 per
clinic. The native populations of the study area are
Chagga. People’s main occupation is agriculture, which
comprise of subsistence coffee, maize, beans and banana
farming as well as animal keeping.
Adult patients using ART for at least 6 months and
who were regular clients of the CTC clinic (rather than
temporary visitors) were eligible to participate. Patients
were approached during routine clinic visits from Febru-
ary 2010 to March 2010. The researchers were introduced
to eligible patients by the CTC staff and explained that
the aim of the study was to explore the experiences of the
patients in their medication use, their perceptions about
facilitators and barriers of adherence, and how being ad-
herent could be facilitated. Patients were informed that
participation in the study was voluntary and that refusal
would not affect their relationship with their health care
provider. A total of 61 patients were conveniently selected
to participate in the study from the four CTC clinics. The
study patients were approached on their clinic appoint-
ment day and asked to participate in the study. All
patients who agreed to participate provided a signed con-
sent. The research was approved by the Tanzania National
Institute for Medical Research (NIMR).
Data collection methods and tools
The research team consisted of two experienced
researchers and three trained research assistants who
were not part of the community where the study was
conducted. This was intentionally done to avoid patients
feeling uncomfortable to discuss their disease and the
challenges they faced, and avoid inducing fear of HIV
status disclosure. All researchers were trained on how to
systematically conduct the interview. They were also
trained to first create an open atmosphere and ensure
patients that all information would be kept confidential
and anonymous. The interviews were pilot -tested in a
clinic where data was not collected. The interview ques-
tions were guided by key-behavioral determinants
explained in the introduction. Hence the interview guide
consisted of topics addressing: 1. Patient’s knowledge
about adherence, 2. Motivational factors (attitudes, emo-
tions, norms of important others, and perceived behav-
ioral control), 3. Barriers and facilitators of adherence
(individual, interpersonal, treatment or health care fac-
tors) and 4. Strategies for improving adherence. Since
this was a semi-structured interview, the interview guide
was used as a tool to help interviewers ask questions in
a flexible way and to follow up on previously identified
themes. All interviews were conducted in Kiswahili
(Tanzania’s national language), in a quiet place in the
hospital. The interviews were recorded using digital
recorders and transcribed verbatim. The transcribed text
from each participant was independently translated by
two researchers from Kiswahili to English.
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Data analysis
Data from the interviews were analyzed manually using
content framework analysis [14]. The procedure involved
identifying and coding the data into respective topics fol-
lowed by interpretation. All five interviewers separately
identified themes and later agreed on common themes.
The thematic framework was identified by relating back
to the theoretical framework original study aims and
objectives and incorporating emerging issues and con-
cepts. The framework was used to develop themes and
categories of themes. Interpretation concerned defining
concepts, mapping array and nature of the phenomena,
and categorizing responses that had similar qualities or
characteristics.
Results
Sixty-one patients (36 female and 25 male) took part in
the study. Their mean age was 34 years (range: 18–60
years). Nearly half (44%) of the participants were mar-
ried, 20% widowed, while the proportion of single and
divorced patients was 18% for both. The majority of par-
ticipants (62%) had completed primary education, 16%
had some level of secondary education, and 18% had few
years of primary education or no education. The socio-
demographic and treatment characteristics of the study
participants are shown in Table 1.
Understanding the concept of adherence
With regard to patients’ knowledge about ART adher-
ence, all participants demonstrated to understand that
they are supposed to take the pills at the right time and
lifelong. Common statements regarding adherence to
ART were “To take pills as instructed”, “To observe time
in taking pills” and “To take pills without stop”. How-
ever, patients also had misconceptions about adherence,
which were mainly related to alcohol consumption.
Patients indicated that the use of alcohol was strictly
prohibited to patients on ART, or that ART should not
be taken after alcohol had been consumed because then
it would not work anymore. For example, 42 years-old-
man said “We have been told that this medicine does not
work well with alcohol” and another man aged 39 years
said “I sometimes stop the medicine because; once you
start using this pill it is not allowed to drink alcohol”.
Beliefs that motivate or de-motivate ART adherence
When asked to explain what motivates them to continue
with ART, nearly two-third (60%) of respondents gave
reasons such as: improved health after starting ART, the
desire to live and take care of children, wanting to live
like others without HIV, and the desire of approval from
health providers at the clinics. The following quotations
illustrate these internal and external motivational drives:
“I am motivated because my health has improved a lot. I
will never stop using the medication, maybe until when
ARTs are out of stock or no longer produced” (Female, 41
years); “I don’t want to die. If I stop using ART I will die.
I want to live longer in order to take care of my family”
(Female, 36 years); “I have to adhere to the treatment be-
cause I want to live like an ordinary person” (Male, 47
years);“There was a time I missed my medication for one
month; when I went to the hospital nurses were mad at
me. I learned that if I don’t adhere next time I will be in
trouble again” (Male, 42 years).
On the other hand, religion contributed to a lower
adherence motivation among some patients, since five
patients indicated that they were discouraged from con-
tinuing taking their pills after being prayed for as an act
of faith by some religious groups. For example a woman,
46 years said “There is a religious group in our village
who pray for us and ask us to stop taking the ART to
demonstrate our faith in healing”. Patients also mentioned
Table 1 Socio-demographic& disease characteristics of
participants
Characteristics Number (n = 61) %
Gender
Female 36 59.1
Male 25 40.9
Age
18–29 3 4.9
30-49- 43 70.5
50+ 11 18.0
Missing 4 6.6
Marital Status
Single 11 18.0
Married 27 44.3
Divorced 11 18.0
Widow 12 19.7
Education
No education 3 4.9
Incomplete primary 8 13.1
Standard seven 38 62.3
Secondary 10 16.4
College/University 2 3.3
Year Started ARV
1999-2001 4 6.6
2002-2004 8 13.1
2005-2007 22 36.0
2008-2009 27 44.3
HIV Disclosure
Disclosed 53 86.9
Not disclosed 8 13.1
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that some patients stopped taking their pills after their
health status had improved, because they felt well and did
not perceive a pressing need to continue with the
medication.
Barriers to ART adherence at the individual level
Alcohol use was not only a reason for intentional non-
adherence due to not understanding how to use the
medications in relation to alcohol consumption, it was
also reported as causing lack of consistency in taking
medication when drinking alcohol. For example, a
woman aged 30 years said: “My husband does not have
regular time to take the medication because he drinks al-
cohol a lot. He can take pills even at midnight sometimes
if he is drunk he doesn’t take the pills until next day.”
Another patient (Male, 60 years) responded when asked
what he perceived to be a barrier to adherence said
“Binge drinking is a big problem”. Inaccessibility of suffi-
cient food was also mentioned as one of the barriers to
ART adherence. A female of 47 years said: “If you don’t
have enough food it is difficult to take the medicines;
these medicines are very strong so you must eat well”.
Another male patient said: “It is hard to adhere to medi-
cation because after taking the medicines I need to eat
and if you don’t have food you decide to stop the
medicine”.
Barriers and facilitators at the interpersonal and
community level
Stigma and disclosure concerns were identified as poten-
tial barriers to ART adherence. It was noted that nearly
a quarter (23%) of patients avoid going to a nearby CTC
clinic due to the fear that fellow community members
may get to know their positive HIV status. In other
words, they choose to enroll in a CTC clinic further
away from their homes to avoid being identified by their
fellow community members. Moreover, some feared to
disclose their status due to the fear of being stigmatized.
For example, a 49-years-old male said: “No one knows
that I am under ART, I can’t tell my wife or relatives.
They will tell everybody”. It was also noted that some
patients avoid disclosing their positive HIV status to
their parents and loved ones because they do not want
to hurt them. A male participant of 44 years said: “My
parents will feel very bad if they find out about my posi-
tive HIV status”. Another female of 45 years said: “I can’t
tell my parents. They have high blood pressure; I don’t
want them to be in trouble”. Yet another participant
(male, 49 years) said, “I have disclosed to my young
brother, my wife and few relatives, who understand me.
But I have not told my parents, they can die”.
On the other hand, disclosure of HIV positivity was
perceived as a facilitator of adherence. We noted that
87% of the study patients had disclosed their HIV status
to other people, particularly to family members or HIV
positive friends. Five respondents said that everyone in
the community knows their status because they are peer
educators and members of the People Living with HIV/
AIDS (PLWHA) group. From the interviews we also
noted that those who had disclosed their HIV status, es-
pecially to family members, received support like assist-
ance in household chores during sickness. Moreover, the
people to whom they had disclosed their HIV status
reminded them about pill taking. Children were men-
tioned as the most important group of people in remind-
ing parents about their medication. For example, a 40-
year-old woman stated “My children are very supportive
especially in reminding me about pill taking”, yet a
woman aged 60 years added, “My children remind me”
and a man aged 33 years said “My wife and few relatives
whom I disclosed to, remind me
Barriers and facilitators at the treatment and health care
level
When asked to share their experiences on taking ART,
only six patients said they did not face difficulties in tak-
ing the medication while the others indicated to have
had some difficulties, particularly related to the occur-
rence of side effects such as feeling sleepy or hungry,
having swollen legs, neuropathy, diarrhea and joint
pains: “When I started my ART, I experienced headaches
and vomited most of the times. But nowadays I don’t feel
that problem anymore.” (Male, 50 years). Out of 55
patients who experienced side effects, 31 (56%) said the
side effects lasted for a short period, whereas 20 (33%)
patients experienced severe side effects and had to
change to another type of medication. However, patients
did not indicate that these side effects influenced their
adherence.
Regarding the care provided, six participants reported
that there are times the CTC clinics run short of pills. In
such cases patients either do not get medication at all,
or they are given an insufficient number of pills. In
addition, some respondents said “Sometimes doctors
make mistakes: they give a next appointment date that
does not correspond with the number of pills dispensed”.
For example a female patient aged 47 years said: “It is
common to finish drugs before the appointment date.
This month I missed pills for two days before my ap-
pointment day was due.” Another observation was that
because CTC clinics sometimes dispense too few pills,
some patients share their pills with a friend or spouse
when one runs short of medication. For example, a 46-
years-old woman said: “I have a neighbor whom we share
medicines, if one runs short of drugs”.
Regarding the organization of the ART clinic, some
patients indicated dissatisfaction about the set-up of the
clinic. For example, a male patient aged 37 years remarked:
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“Separation of the CTC clinic from the other department
buildings of the hospital is a problem because when one
goes to collect the ARVs, there is fear that other people will
know our problem”.
Finally, the active role of trained home based care
(HBC) providers who bring medication to patients at
their homes in case of illness, were indicated by the
majority of patients as being an important facilitator of
adherence.
Patients’ suggestions for strategies to improve adherence
As regards to measures to be taken to improve ART ad-
herence, the majority of patients recommended firstly
the improvement of services at the CTC clinics, and par-
ticularly the availability of pills at the clinics at all times.
Furthermore, patients recommended the involvement of
PLWHA to be recruited as HBC providers because they
felt that they would be more acceptable to patients. They
also said it would be helpful to have more social support
from family members such as reminding them to take
medication, supporting them with food and helping
them in house hold chores on occasion of illness. Finally,
and linked to the perceived importance of social support,
the majority of patients indicated that addressing the
problem of stigma through provision of appropriate edu-
cation to patients as well as to communities would im-
prove ART adherence as the following quotes from
patients indicate “I would like the surrounding commu-
nity to be educated and understand the disease and stop
stigmatizing and, help me with food”.(Male, 41 years).
Another female aged 42 years responded “Community
members should be educated not to stigmatize me but co-
operate with me”
Discussion
Poor adherence to ART is a well-known problem with
implications for patients’ and public health due to the
spread of (resistant) HIV [15]. This study sought to iden-
tify the most relevant determinants of adherence
through interviews with 61 patients in 4 different health
clinics in northern Tanzania anno 2010, six years after
the introduction of ART in the region. Our findings in-
dicate that the majority of patients have a basic under-
standing of the meaning of adherence to medication.
The perception of improved health, the desire to live a
similar life as non-infected community members, having
children and being a good parent were identified as key-
adherence motivating factors. Support from friends and
family members and the active role of home based care
providers were important facilitators of adherence. The
use of alcohol, the unavailability of food, stigma, status
disclosure concerns, and the clinics dispensing too few
pills were identified as potentially important barriers to
adherence. These findings suggest avenues for supporting
adherence through changes at the individual, interper-
sonal, community and health care level.
According to behavioral theories, patients’ knowledge
about a health behavior forms the basis for their so-
called outcome expectancies, and the value attached to
these outcomes which shapes people’s attitudes towards
the behavior [7,16]. In the present study, the majority of
patients had adequate basic understanding on adherence
in the sense that they are supposed to take pills at the
right time and lifelong. However, there was also what we
perceived to be a common misunderstanding concerning
taking medication and the use of alcohol. Some patients
stop taking medication because they believe that one
should not drink at all (not even incidentally and mod-
erately) while on ARV. Hence, since alcohol drinking is
part of culture in the study area, many patients are faced
with dilemma to either stop drinking alcohol completely
and take medication, or stop medication even when they
drink a moderate amount of alcohol on a particular oc-
casion. Similar beliefs have also been observed in a study
by Sankar (2007), who found that 85% of his African-
American respondents strongly believed that ART and
alcohol do not go together [17]. What our study identi-
fied was that this belief about alcohol use seems to be, at
least in this region, mainly introduced by the health care
providers. No doubt their intention was to limit prob-
lematic alcohol (i.e., upon inquiry health care providers
reported to do this for general health, promotion of safe
sex, and to tackle the problem of excessive alcohol use
while on ART) while keeping patients on ART, rather
than patients not taking the medication when drinking
(some) alcohol. However, the practice of prohibiting
alcohol use completely when or ARV’s, which for many
patients may be unrealistic, seems counterproductive and
it is also not required from a pharmacological viewpoint.
Hence, this finding suggest that in addition to patients
with problematic drinking behavior, health care providers
should be the focus of intervention efforts since they can
better acknowledge that patients will consume alcohol,
and instead of prohibiting alcohol discuss with patients
under what conditions alcohol use is acceptable.
Knowledge and motivations are not only based on in-
formation received from others, but also arises from
experiences patients have had with the treatment [9].
With regard to this aspect, patients mentioned improved
health after the start of ART as a motivation to continue
with ART. However, this same experience also turned
out to de-motivate some other patients, since they
stopped the use of ART after their health had improved.
The latter perception has also been observed in other
studies, where patients indicated difficulties in adhering
during times of decreased symptoms [18,19]. The
patients presumably felt less urgency to continue with
the medication because the symptoms, which initially
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prompted them to take their medication, disappeared. It
seems that to prevent this problem, it is important that
health care providers intervene on the belief that medi-
cation is only required or beneficial when symptoms are
present. Instead, as some patients indicated in this study,
improved health is ideally perceived as a reason to con-
tinue the treatment because of its experienced benefits.
Although the key difference between patients experien-
cing improved health as a reason to continue versus dis-
continue treatment were not identified in this study, a
logical explanation seems to be the level of understand-
ing or belief in how the disease and the treatment works
i.e., patients’ explanatory model of the disease and treat-
ment, cf., [20]. Indeed, although all patients knew the
basic instructions for medication intake, very few
patients in this study displayed understanding of how
HIV works, affects the body and how the treatment dis-
rupts that process. Hence, improved understanding of
these (long-term) processes may prevent patients to halt
treatment when symptoms disappear. Other key motiv-
ational beliefs were also identified, namely the need to
take care of one’s family and the desire to live like an or-
dinary person. Identifying these key needs no an individ-
ual level, and linking them long-term adherence to these
beliefs (in line with Motivation Interviewing and the
Self-determination theory [21], seems to be important to
induce high levels of motivation to adhere to ART.
Discrepancies between medical knowledge and patient
beliefs were also observed in relation to the power of
prayer, since some patients stopped using ART after they
had been prayed for as an act of faith. Religion is an im-
portant part of life of the people in the study area and
there are number of faith healers who claim to have the
power to heal diseases including HIV/AIDS. Stopping
treatment after prayer has also been observed in other
studies [22-24] and it seems difficult to challenge such
religious beliefs. A possible approach could be to
mobilize church leaders, since they might be the most
trustworthy source for patients to alter such beliefs (i.e.,
rather than physicians, nurses or community workers).
Furthermore, and in accordance with the theories dis-
cussed [7-10], the extent to which patients reported to
be successful in adhering depended on whether their
efforts were being facilitated or obstructed, and on their
self-regulatory skills to cope with such barriers. Factors
that facilitated adherence were at the interpersonal level
(i.e., practical and emotional social support) [25], and at
the health care level (i.e., home-based care providers).
Factors that obstructed adherence were mentioned more
often, and resided at the individual and interpersonal
level (i.e., lack of food, fear for stigma and disclosure) as
well as at the health care level (i.e., lack of privacy at the
clinic, and insufficient availability or provision of pills).
This form of malpractice, namely providing insufficient
pills while stocks were sufficient, was also observed in a
previous study by the authors in the same area [26].
After discussing this with clinics they changed their pro-
cedures and offered patients sufficient pills to bridge the
time between two visits, including a few extra pills in
case the patient could not make it to the clinic at the ap-
pointment date. Regarding the barriers at the individual
and interpersonal level, these seem more difficult to
alter. A lack of food common is common among people
in this region. One recommended strategy is that health
care providers discuss with patients facing this problem
whether they can more strategically ration their food
and otherwise take the medication in the absence of
food (since first-line treatments in this region do not
need to be combined with food). Another strategy is to
attempt to reduce the financial burden for patients by
lowering visit frequency to the clinic for adherent
patients [27] or linking them with microcredit schemes
[28]. Regarding the interpersonal level, successful, well-
conducted stigma-reducing interventions are scarce al-
though a recent review reveals there are several promis-
ing programs that can be adopted [29].
Side-effects were also reported by many patients as a
problem, although the participants in the current study
indicated that this did not affect their adherence, which
is contrary to findings in many other studies in which
side effects were found to hamper adherence e.g.,
[30,31]. This could be explained by the fact that patients
in this area had an option to switch to another regimen,
or simply by the fact that participants in this study were
those patients still retained in treatment (i.e., those with
severe side effects are more likely to drop out) [29].
Hence reported ways of dealing with barriers were chan-
ging medication by the health care provider, who should
systematically inquire about such issues, and taking the
medication until the side-effects resided.
Regarding strategies to improve adherence, our
respondents recommended that the clinics should be
integrated into the other services provided by the health
care institution to maintain discretion. Some patients
turned to clinics further away from their homes in order
to avoid being recognized when visiting the clinic, which
introduces additional barriers to the continued use of
care due to the travel distance. Patients also indicated
that clinics should provide sufficient pills and they
stressed the importance of social support and the reduc-
tion of stigma about HIV in the community. Hence,
patients perceived the key challenges to adherence to
reside in their environment. Although these recommen-
dations are highly valuable, the results of this study also
suggest it is key to address behavioral determinants at
the individual level: knowledge and misconceptions
about the treatment and adherence; motivation to con-
tinue ART use despite waning of symptoms; skills and
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confidence for disclosure, coping with stigma, alcohol
use and other barriers to taking ART continuously and
life-long.
These findings and patients’ suggestions have broader
implications for other HIV care in Tanzanian clinics as
well as for future research. In sum, our recommendations
for supporting adherence based on this study are, first, to
improve counseling by the health care providers [c.f., 32].
This counseling should focus on providing patients a dee-
per understanding of how HIV and the treatment works
and the responsible use of alcohol (knowledge); appealing
to patients’ personally relevant goals achieved through ad-
hering to the treatment (e.g., ability to take care of family)
and reducing de-motivating factors (such as dealing with
side-effects or promoting disclosure to deal increase a
sens of support) [33]; and dealing with barriers such as a
lack of food. Clinic changes recommended are to always
provide patients with a more than sufficient amount of
pills and to allow patients to keep their HIV status confi-
dential by not creating a separate location for HIV treat-
ment in the clinic. Finally, community support (or at
least, a reduction of perceived stigma) and eradicating the
belief that prayer can cure HIV could be tackled by com-
bined efforts of community or governmental organiza-
tions and religious leaders. Hence, in order to improve
adherence and quality of life of patients with HIV, a
multi-level health promotion intervention is required
[33,34]. However, which interventions are most effective
and feasible in this setting -also considering the limited
time health care professionals have per patient - should
be subject to future intervention studies.
This study had several limitations. It is a qualitative
study relying on patients self-reports and perception of
adherence influences retrospectively. Moreover, socially
desirable answers may have occurred. Finally, although
there was a relatively large sample size and patients were
selected from four clinics, the sample is too small for the
results to be generalized to all Tanzanian patients and
clinics.
Conclusion
In conclusion, having HIV and adhering to ART remains
to pose substantial challenges to patients in Tanzania. Ad-
herence seems to be affected by multiple factors at the in-
dividual, interpersonal, community and health care level.
Behavioral theories, such as the theory of planned behav-
ior, were useful for structuring the research and guiding
data interpretation. Interventions to support adherence in
the region should ideally be directed at all these factors in
order for patients to adhere and persist to the treatment,
and ultimately for their health and quality of life.
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